REG - Renalytix PLC - Total Voting Rights

RenalytixAnnouncement

28/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240628:nRSb2377Ua&default-theme=true

RNS Number : 2377U  Renalytix PLC  28 June 2024

 

Renalytix plc

("Renalytix" or the "Company")

 

Total Voting Rights

 

LONDON and NEW YORK, 28 June 2024 - Renalytix plc
(http://www.renalytix.com/)  (NASDAQ: RNLX) (LSE: RENX) announces that at
today's date, the Company's total issued share capital is 154,368,191
Ordinary Shares of £0.0025 each in the capital of the Company ("Ordinary
Shares"). Each Ordinary Share carries the right to one vote at a general
meeting of the Company. The Company does not hold any Ordinary Shares in
treasury.

 

The above figure may be used by shareholders in the Company as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change in their interest in, the share capital
of the Company under the Financial Conduct Authority's Disclosure Guidance and
Transparency Rules.

 

For further information, please contact:

 

 Renalytix plc                                                     www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                                             Via Walbrook PR

 Stifel (Nominated Adviser, Joint Broker)                          Tel: 020 7710 7600
 Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea

 Investec Bank plc (Joint Broker)                                  Tel: 020 7597 4000
 Gary Clarence / Shalin Bhamra

 Walbrook PR Limited              Tel: 020 7933 8780 or renalytix@walbrookpr.com

                                (mailto:renalytix@walbrookpr.com)
 Paul McManus / Alice Woodings

                                  Mob: 07980 541 893 / 07407 804 654

 CapComm Partners
 Peter DeNardo                                                     Tel: 415-389-6400 or investors@renalytix.com (http://investors@renalytix.com)

 

 

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an artificial intelligence enabled
in-vitro diagnostics and laboratory services company that is the global
founder and leader in the field of bioprognosis™ for kidney health. In late
2023, our kidneyintelX.dkd test was recognized as the first and only
FDA-authorized prognostic test to enable early-stage CKD (stages 1-3b) risk
assessment for progressive decline in kidney function in T2D patients. By
understanding how disease will progress, patients and clinicians can take
action earlier to improve outcomes and reduce overall health system costs. For
more information, visit www.renalytix.com
(https://urldefense.proofpoint.com/v2/url?u=https-3A__www.globenewswire.com_Tracker-3Fdata-3Dcwptls73WOXXvXZElSs3a2reoferxCWvBpaKyejhK9PSyJybCe1RUrHHx3-2DAhQrHBtzbuyNE2-5F1PQpSvEYREQK8LxkfY8s7gpb-5FVuRJmGhAI9JKKWZjvt-2D05FOQJ9ERDnn2CUUsRBUUidnavSIKVEnBKEYHCV7D6JUNxeV5-2DpdXJh-5FjdHbXPDhXgx0eUmgXXzpbXGMkTlKTYy5JA1S-5FOaAF8hqjwoJBdo-5F1P3A1vfd4EsWBV9RicuAt4kurR-5F7Vd&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=0Ccev-iSYAXL7WGz82NYElc-Zkmi9x-eMePOXIwjAkA&m=govkOI5zR7a6TCy8Dp2muoGOG4mW8_RSqtwnuXPlsmqyrVqDub5ft1Xkg_gYiBPS&s=MJ6gLFWlE0s5okueNj4qGe5eb8XIJQoOwVYXOiCCiy8&e=)
.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRQKOBBABKDOAB